Effect of Pazopanib on Survival After Metastasectomy in Metastatic RCC

The study investigators evaluated the survival benefit of  pazopanib in metastatic renal cell carcinoma patients with no evidence of disease after metastasectomy.

Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news